{"product_id":"patently-innovative-how-pharmaceutical-firms-use-emerging-patent-law-to-extend-monopolies-on-blockbuster-drugs-hardback-9781907568121","title":"Patently Innovative; How Pharmaceutical Firms Use Emerging Patent Law to Extend Monopolies on Blockbuster Drugs (Hardback) 9781907568121","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003ePatently Innovative\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003eHow Pharmaceutical Firms Use Emerging Patent Law to Extend Monopolies on Blockbuster Drugs\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eR A Bouchard (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781907568121, Elsevier Science\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 2 January 2012\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e296 pages\u003cbr\u003e23.3 x 15.6 x 2.3 cm, 0.78 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003ePatently innovative provides a review of the importance of traditional patent law and emerging linkage regulations for pharmaceutical products on the global stage, with a focus on the linkage regime in Canada. The primary focus is on how innovation in the pharmaceutical sector can be strongly regulated and how government regulation can either stimulate or inhibit development of breakthrough products.\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eDedication\u003c\/p\u003e \u003cp\u003eAcknowledgements\u003c\/p\u003e \u003cp\u003eList of figures and tables\u003c\/p\u003e \u003cp\u003eList of abbreviations\u003c\/p\u003e \u003cp\u003eAbout the author\u003c\/p\u003e \u003cp\u003eChapter 1: Introduction\u003c\/p\u003e \u003cp\u003eAbstract:\u003c\/p\u003e \u003cp\u003e1.1 The emergence of global pharmaceutical linkage\u003c\/p\u003e \u003cp\u003e1.2 Canadian pharmaceutical linkage regulations\u003c\/p\u003e \u003cp\u003e1.3 Organization\u003c\/p\u003e \u003cp\u003eChapter 2: Background: drug approval, drug patenting, pharmaceutical linkage, and public health policy\u003c\/p\u003e \u003cp\u003eAbstract:\u003c\/p\u003e \u003cp\u003e2.1 Drug approval\u003c\/p\u003e \u003cp\u003e2.2 Patents\u003c\/p\u003e \u003cp\u003e2.3 Linkage regulations\u003c\/p\u003e \u003cp\u003e2.4 IPR rights and innovation policy\u003c\/p\u003e \u003cp\u003eChapter 3: Empirical analysis of drug approval\u003c\/p\u003e \u003cp\u003eAbstract:\u003c\/p\u003e \u003cp\u003e3.1 Introduction\u003c\/p\u003e \u003cp\u003e3.2 Analysis\u003c\/p\u003e \u003cp\u003e3.3 Results\u003c\/p\u003e \u003cp\u003e3.4 Discussion\u003c\/p\u003e \u003cp\u003e3.5 Interpretation of data\u003c\/p\u003e \u003cp\u003e3.6 Study limitations\u003c\/p\u003e \u003cp\u003e3.7 Assessing the lifecycle approach: the long view\u003c\/p\u003e \u003cp\u003e3.8 Government as representative public agent\u003c\/p\u003e \u003cp\u003e3.9 Summary and conclusions\u003c\/p\u003e \u003cp\u003eChapter 4: Empirical analysis of pharmaceutical innovation and drug approval-drug patenting linkage\u003c\/p\u003e \u003cp\u003eAbstract:\u003c\/p\u003e \u003cp\u003e4.1 Introduction\u003c\/p\u003e \u003cp\u003e4.2 Methods\u003c\/p\u003e \u003cp\u003e4.3 Results\u003c\/p\u003e \u003cp\u003e4.4 Discussion\u003c\/p\u003e \u003cp\u003eChapter 5: Empirical analysis of drug patenting in multiple high-value cohorts\u003c\/p\u003e \u003cp\u003eAbstract:\u003c\/p\u003e \u003cp\u003e5.1 Introduction\u003c\/p\u003e \u003cp\u003e5.2 Methods\u003c\/p\u003e \u003cp\u003e5.3 Results\u003c\/p\u003e \u003cp\u003e5.4 Discussion\u003c\/p\u003e \u003cp\u003e5.5 Summary and conclusions\u003c\/p\u003e \u003cp\u003eChapter 6: Implications of empirical data: are pharmaceutical linkage regulations a success?\u003c\/p\u003e \u003cp\u003eAbstract:\u003c\/p\u003e \u003cp\u003e6.1 Introduction\u003c\/p\u003e \u003cp\u003e6.2 Debate preceding Bill C-91\u003c\/p\u003e \u003cp\u003e6.3 ‘Original policy intent’\u003c\/p\u003e \u003cp\u003e6.4 ‘Patent-specific’ analysis\u003c\/p\u003e \u003cp\u003e6.5 Statutory interpretation\u003c\/p\u003e \u003cp\u003e6.6 Revisiting the empirical data\u003c\/p\u003e \u003cp\u003e6.7 Summary and conclusions\u003c\/p\u003e \u003cp\u003eChapter 7: Future directions: testable hypotheses and evolution toward global pharmaceutical linkage\u003c\/p\u003e \u003cp\u003eAbstract:\u003c\/p\u003e \u003cp\u003e7.1 Hypotheses regarding cluster-based drug development\u003c\/p\u003e \u003cp\u003e7.2 Globalization of pharmaceutical linkage\u003c\/p\u003e \u003cp\u003eIndex\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Pharmacology [\u003ca title=\"See our other books on Pharmacology\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Pharmacology%20%5BMMG%5D%22\"\u003eMMG\u003c\/a\u003e], Intellectual property law [\u003ca title=\"See our other books on Intellectual property law\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Intellectual%20property%20law%20%5BLNR%5D%22\"\u003eLNR\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Woodhead Publishing","offers":[{"title":"Default Title","offer_id":46648835506456,"sku":"9781907568121","price":105.65,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/products\/9781907568121_b119ef20-90b9-42c4-a399-0916db031eeb.jpg?v=1696598736","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/patently-innovative-how-pharmaceutical-firms-use-emerging-patent-law-to-extend-monopolies-on-blockbuster-drugs-hardback-9781907568121","provider":"Freshly Printed Books","version":"1.0","type":"link"}